Literature DB >> 32106196

Experience and Satisfaction of Cancer Patients With a Central Venous Catheter at a Tertiary Hospital in South Korea.

Jeong Yun Park1,2,3, Da In Lee1,2,3.   

Abstract

As cancer chemotherapy transitions from inpatient care to outpatient care, the number of patients who receive a central venous catheter (CVC) and the interest in CVCs as a safe intravenous administration route have increased recently in South Korea. The purpose of this study was to investigate the discomforts and satisfaction that cancer patients with a CVC may experience in daily activities as an outpatient and to provide rationale for nursing interventions. Data collection was conducted between April 11, 2011, and August 31, 2011. Forty-three questionnaires were collected, and a total of 41 questionnaires were used for the final analysis. The mean age of patients was 45.1 years (SD = 11.1 years; range, 18-64 years). The average score of experience of the CVC insertion procedure, daily life experiences of patients with a CVC, the satisfaction and fear of using a CVC, and the acceptance of CVCs were 2.48 ± 0.56, 2.18 ± 0.50, 2.56 ± 0.49, and 2.35 ± 0.39, respectively. The results showed that more detailed information on CVCs, as well as sufficient emotional support, should be provided to the patient to minimize discomfort during CVC insertion. Patient-centered education helps empower patients to master CVC self-management, as well as an understanding of the cultural aspect of South Korean patients who practice the traditional Confucian ethics of "unaltering one's body" and are therefore reluctant to have CVCs inserted into their bodies.

Entities:  

Mesh:

Year:  2020        PMID: 32106196     DOI: 10.1097/NAN.0000000000000360

Source DB:  PubMed          Journal:  J Infus Nurs        ISSN: 1533-1458


  1 in total

Review 1.  Adult oncology patients' experiences of living with a central venous catheter: a systematic review and meta-synthesis.

Authors:  Dhurata Ivziku; Raffaella Gualandi; Francesca Pesce; Anna De Benedictis; Daniela Tartaglini
Journal:  Support Care Cancer       Date:  2022-01-14       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.